Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Alpha Teknova Community
NasdaqGM:TKNO Community
1
Narratives
written by author
0
Comments
on narratives written by author
3
Fair Values set
on narratives written by author
Create a narrative
Alpha Teknova
Popular
Undervalued
Overvalued
Community Investing Ideas
Alpha Teknova
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Acquisitions And Collaborations Will Expand Cell And Gene Therapy Portfolio
Key Takeaways Expansion through collaborations and acquisitions aims to boost top-line growth, margins, and financial stability amidst anticipated market rebound. Focus on supporting Cell and Gene Therapy promises substantial revenue gains from clinical phase progressions, while custom product growth targets strengthen revenue prospects.
View narrative
US$11.00
FV
36.7% undervalued
intrinsic discount
13.10%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
11 days ago
author updated this narrative
Your Valuation for
TKNO
TKNO
Alpha Teknova
Your Fair Value
US$
Current Price
US$6.96
532.7% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-51m
76m
2015
2018
2021
2024
2025
2027
2030
Revenue US$75.7m
Earnings US$9.2m
Advanced
Set Fair Value